The Neuroendocrine Tumor Research Foundation (NETRF) awards grants to nine investigators, including one of UKINETS’ founding members, Prof Martyn Caplin.
The Neuroendocrine Tumor Research Foundation has awarded $2.62 million in grants to advance research aimed at finding new and innovative treatments for neuroendocrine tumors (NETs).
The awards support three international awardees from the global NET research community and six of the nine awardee institutions received NETRF support for the first time. NETRF’s latest round of awards provides critical funding for unique projects on NETs, addressing both basic and translational research. Three of the grants focus on research on gastrointestinal NETs, three on pancreatic NETs, two on multiple NETs types, and one on pheochromocytomas and paragangliomas.
The latest round of grant support brings the total NETRF research investment to $30 million over the past 15 years.
Supporting transformational ideas
Innovative and transformative research ideas that can bring the field of NET closer to more effective therapies are the cornerstone of NETRF’s annual research awards. The Foundation offers four different neuroendocrine cancer research grants (Accelerator, Investigator, Mentored, and Pilot Awards), with awards ranging from $100,000 to $1.2 million.
NETRF granted its Petersen Accelerator Award to Martyn Caplin, DM, FRCP, of the University College London, to study mesenteric fibrosis in NETs originating from the small intestine.
“This collaborative study across two European NET Centers addresses an important unmet need in NET research,” said NETRF Director of Research John Kanki, PhD. “A better understanding of fibrosis and its role in the clinical outcomes of NET patients may have a significant impact on clinical care.”
To find out more, please visit the NETRF website…